Genomes and Genes
Summary: Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Publications259 found, 100 shown here
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBrian G Till
Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 112:2261-71. 2008b>Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously been explored for the treatment of lymphoma in human subjects...
- Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesMark E Dudley
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
Science 298:850-4. 2002..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
- CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cellsPaul A Antony
Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 174:2591-601. 2005..Paradoxically, we found that absence of CD4(+) T cells enhanced adoptive immunotherapy of cancer when using CD8(+) T cells directed against a persisting tumor/self-Ag...
- NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivoTadepally Lakshmikanth
Department of Experimental and Clinical Medicine, University of Catanzaro Magna Graecia, Italy
J Clin Invest 119:1251-63. 2009....
- Adoptive immunotherapy of cancer using CD4(+) T cellsPawel Muranski
National Cancer Institute, NIH, Bethesda, MD 20892, USA
Curr Opin Immunol 21:200-8. 2009....
- Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapyMala Chakraborty
Laboratory of Tumor Immunology and Biology and Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 170:6338-47. 2003..We examined the effect of localized irradiation of s.c. growing tumors on the efficiency of CTL adoptive immunotherapy. Irradiation caused up-regulation of Fas by these tumor cells in situ, based on immunohistochemistry...
- Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?Pawel Muranski
Clinical Research Center, National Institutes of Health, Room 3 5762, Bethesda, MD 20892, USA
Nat Clin Pract Oncol 3:668-81. 2006..Here we review recent advances in adoptive immunotherapy of solid tumors and discuss the rationale for lymphodepleting conditioning...
- Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancerRajeev K Shrimali
Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
Cancer Res 70:6171-80. 2010..These studies provide a rationale for the exploration of combining antiangiogenic agents with ACT for the treatment of patients with cancer...
- Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytesJehonathan H Pinthus
Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
J Clin Invest 114:1774-81. 2004..These preclinical studies strongly support the idea that the T body approach has therapeutic potential in disseminated prostate cancer...
- Role of immature myeloid Gr-1+ cells in the development of antitumor immunityQingsheng Li
Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, New York, USA
Cancer Res 64:1130-9. 2004....
- An inducible caspase 9 safety switch for T-cell therapyKarin C Straathof
Center for Cell and Gene Therapy, Baylor College of Meidcine, Houston, TX 77030, USA
Blood 105:4247-54. 2005..Third, inducible caspase 9 maintains function in T cells overexpressing antiapoptotic molecules. These characteristics favor incorporation of inducible caspase 9 as a safety feature in human T-cell therapies...
- Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantationD Sangiolo
Institute for Cancer Research and Treatment IRCC, Laboratory of Medical Oncology, Strada Provinciale 142, Candiolo TO, Italy
Expert Opin Biol Ther 9:831-40. 2009..The finding of new cell populations for adoptive immunotherapy, with the ability to separate GVT from GVHD, would be useful...
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinomaDaniel H Palmer
Cancer Research UK Clinical Trials Unit, CR UK Institute for Cancer Studies, Clinical Research Block
Hepatology 49:124-32. 2009..Immune responses were assessed using an ELIspot assay of interferon-gamma (IFN-gamma) release. In several cases there was induction of T cell responses to the vaccine and/or AFP following vaccination...
- Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphomaM R Verneris
Department of Medicine, Stanford University School of Medicine, California 94305, USA
Biol Blood Marrow Transplant 7:532-42. 2001..GVT activity is dependent on perforin, but not on Fas-ligand. We conclude that expanded CD8+ NK-T cells may serve as a valuable adjuvant population for allogeneic HCT because they mediate GVT effects with minimal GVHD...
- Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigenRosalind Polley
Immunology and Infection Unit, Dept of Biology, University of York, P O Box 373, York YO10 5YW, United Kingdom
Infect Immun 74:773-6. 2006..Here, we demonstrate that successful adoptive immunotherapy with CD8+ T cells is strictly dependent upon the presence of cognate antigen.
- De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor modelZ Sheng Guo
Thoracic Oncology Section and Tumor Immunology Section, Surgery Branch, National Cancer Institute NIH, Bethesda, MD 20892, USA
Cancer Res 66:1105-13. 2006..These data show a novel strategy of combined chemoimmunotherapy of cancer targeting a CTA induced de novo in a broad range of tumor histologies, and support further evaluation of chromatin-remodeling agents for human cancer therapy...
- Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritisGraham P Wright
Department of Immunology, University College London, Royal Free Hospital, London NW3 2PF, United Kingdom
Proc Natl Acad Sci U S A 106:19078-83. 2009..This opens the possibility to target Tregs to tissue-specific antigens for the treatment of autoimmune tissue damage without the knowledge of the disease-causing autoantigens recognized by pathogenic T cells...
- Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapyJuhua Zhou
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 175:7046-52. 2005Recent studies have indicated that adoptive immunotherapy with autologous antitumor tumor-infiltrating lymphocytes (TILs) following nonmyeloablative chemotherapy mediates tumor regression in approximately 50% of treated patients with ..
- Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradicationRuth Ganss
Department of Molecular Immunology, German Cancer Research Center, 69120 Heidelberg, Germany
Cancer Res 62:1462-70. 2002..Therefore, irradiation/adoptive transfer therapy combines antigen-driven tumor cell eradication with anti-angiogenic effects on tumor endothelium, a powerful synergy that has not been previously appreciated...
- Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanomaAndreas Mackensen
Department of Hematology Oncology, University of Regensburg, Franz Josef Strauss Allee 11, D 93042 Regensburg, Germany
J Clin Oncol 24:5060-9. 2006..A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients...
- Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomasDe sheng Weng
State Key Laboratory of Oncology in Southern China, Biotherapy Center, Department of Imaging and Interventional Radiology, Sun Yat Sen University, Guangzhou, Guangdong, P R China
J Immunother 31:63-71. 2008The recurrence of hepatocellular carcinoma (HCC) after minimally invasive therapy is frequent. Adoptive immunotherapy is thought to be an effective method to lower recurrence and metastasis rates of malignant tumors...
- Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancerK Birkholz
Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
Gene Ther 16:596-604. 2009..with a new defined specificity by expression of a chimeric T-cell receptor (immunoreceptor) for the use in adoptive immunotherapy of cancer...
- Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cellsTontanai Numbenjapon
Division of Molecular Medicine, Beckman Research Institute and City of Hope National Medical Center, Duarte, Calif, USA
Exp Hematol 35:1083-90. 2007..to express a first-generation CD19-specific chimeric antigen receptor (CAR), designated CD19R, for adoptive immunotherapy of B-lineage leukemias and lymphomas...
- Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunitG L Costa
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
J Immunol 167:2379-87. 2001..we used the site-specific trafficking properties of autoantigen-reactive CD4+ T cells to develop an adoptive immunotherapy protocol that provided local delivery of a Th1 cytokine antagonist, the p40 subunit of IL-12...
- Effect of selenium on the immunocompetence of patients with head and neck cancer and on adoptive immunotherapy of early and established lesionsL Kiremidjian-Schumacher
Division of Biological Sciences, Medicine, and Surgery, New York University College of Dentistry, New York, NY 10010, USA
Biofactors 14:161-8. 2001..The combined data suggested that local immunotherapy with IL-2 in hosts supplemented with Se may represent an effective modality of treatment for the prevention of recurrences at the site of conventionally treated primary tumors...
- Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionalityRozemarijn S van Rijn
Jordan Laboratory for Hemato Oncology, Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
Exp Hematol 35:117-27. 2007Recent clinical trials of adoptive immunotherapy showed diminished reactivity of human T cells upon ex vivo manipulation...
- Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat modelP J Kuppen
Dept of Surgery, Leiden University Medical Center, The Netherlands
Immunol Rev 184:236-43. 2001..Our results indicate that NK-cell cancer therapy is still promising and needs improvement...
- Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft modelS H Yoon
Department of Microbiology and Immunology, College of Medicine, Catholic University of Korea, Seoul, Korea
Cancer Gene Ther 16:489-97. 2009..These results provided evidence that electroporation of CIR RNA to human PBLs could be used for rapid generation and high number of therapeutic antigen-specific T cells for adoptive immunotherapy.
- Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell linesKarl S Peggs
Royal Free and University College London Medical School, London, UK
Lancet 362:1375-7. 2003..Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment...
- Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative diseaseDavid M Burns
Basic and Clinical Virology Laboratory, Section of Medical Microbiology, University of Edinburgh, R D VS, Summerhall, Edinburgh EH9 1QH, UK
Blood Rev 18:193-209. 2004..An alternative, adoptive immunotherapy, involving the administration of EBV-specific CTLs cultured in vitro has been developed with the aim of ..
- Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapyM Hoogendoorn
Laboratory of Experimental Hematology, Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
Leukemia 18:1278-87. 2004..These results show the feasibility of ex vivo generation of B-CLL-reactive CD8(+) CTLs. This opens new perspectives for adoptive immunotherapy, following allogeneic stem cell transplantation in patients with advanced B-CLL.
- Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapyJuhua Zhou
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunother 28:53-62. 2005The authors recently reported that adoptive immunotherapy with autologous tumor-reactive tumor infiltrating lymphocytes (TILs) immediately following a conditioning nonmyeloablative chemotherapy regimen resulted in an enhanced clinical ..
- Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trialKoji Kono
First Department of Surgery, Yamanashi Medical University, 1110 Tamaho, Yamanashi 409 3898, Japan
Clin Cancer Res 8:1767-71. 2002We performed adoptive immunotherapy (AIT)with tumor-associated lymphocytes (TALs) in combination with chemotherapy in patients with advanced-stage gastric cancer in a randomized controlled study and investigated whether or not an improved ..
- Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanomaEduardo Huarte
Department of Medicine, Lebanon, NH 03756, USA
Cancer Lett 285:80-8. 2009....
- Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's diseaseCatherine M Bollard
Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
J Exp Med 200:1623-33. 2004..clearly identified tumor antigens derived from the virus and could, in principle, be a target for adoptive immunotherapy with viral antigen-specific T cells...
- Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cellsL J Berry
Cancer Immunology Program, Peter MacCallum Cancer Centre, Victoria, Australia
Tissue Antigens 74:277-89. 2009..This review discusses the latest developments in the field of adoptive immunotherapy using genetically modified immune cells that have been transduced with either TCR or scFv receptor ..
- Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cellsJingting Jiang
The Third Affiliated Hospital, Suzhou University, Changzhou 213003, China
Anticancer Res 26:2237-42. 2006..It is concluded that chemotherapy plus CIK cells has obvious benefits for patients who suffer from advanced gastric cancers...
- Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancerChangping Wu
The Third Affiliated Hospital of Suzhou University, Changzhou 213003, PR China
Anticancer Res 28:3997-4002. 2008..It was concluded that chemotherapy plus CIK cells has potential benefits compared to chemotherapy alone in patients suffering from advanced NSCLC and autologous CIK cell transfusion has no obvious side-effects...
- Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumorMichael S Sabel
University of Michigan, Department of Surgery, Division of Surgical Oncology, 3304 Cancer Center, 1500 East Medical Center, Ann Arbor, MI 48109 0932, USA
Cryobiology 53:360-6. 2006..We examined whether cryoablated tumor draining lymph nodes (CTDLN) as adoptive immunotherapy may be an effective immunotherapeutic approach in the adjuvant treatment of breast cancer...
- Adoptive T cell therapy for cancer in the clinicCarl H June
Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
J Clin Invest 117:1466-76. 2007..Improved molecular biology techniques have also increased enthusiasm and feasibility for testing genetically engineered T cells. The current status of the field and prospects for clinical translation are reviewed herein...
- The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cellsOliver Frey
Institut fur Pathologie, Friedrich Schiller Universitat, Jena, Germany
Arthritis Res Ther 7:R291-301. 2005..However, transferred Treg cells appear to be unable to counteract established acute or chronic inflammation. This is of considerable importance for the timing of Treg cell transfer in potential therapeutic applications...
- Graft-versus-leukemia effects of transplantation and donor lymphocytesHans Jochem Kolb
Department of Medicine 3, Hematopoietic Cell Transplantation, University of Munich and Helmholtz Zentrum Muenchen National Research Centre for Environmental Health, Munich, Germany
Blood 112:4371-83. 2008..Recently, we have learned from adoptive immunotherapy of viral diseases and HLA-haploidentical stem cell transplantation that T-cell memory may be essential for ..
- Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2Sameek Roychowdhury
Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio 43210, USA
Cancer Res 64:8062-7. 2004b>Adoptive immunotherapy with tumor-specific T cells has emerged as a valid approach for prevention or treatment of diseases, such as melanoma and EBV-associated lymphoma...
- Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical studyJohn K Chan
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
Clin Cancer Res 12:1859-67. 2006..Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. The mechanism of cytolysis seems to be mediated in part by the NKG2D receptor...
- Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignanciesStephen Gottschalk
Center for Cell and Gene Therapy, Texas Children s Cancer Center, Departments of Pediatrics, Medicine, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
Blood 101:1905-12. 2003..Thus, DeltaLMP1 expression in DCs is nontoxic and enables the generation of LMP1-specific CTLs for future adoptive immunotherapy protocols for patients with LMP1-positive malignancies such as EBV-positive Hodgkin disease...
- Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cellsMathias Oelke
Department of Pathology and Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Nat Med 9:619-24. 2003b>Adoptive immunotherapy holds promise as a treatment for cancer and infectious diseases, but its development has been impeded by the lack of reproducible methods for generating therapeutic numbers of antigen-specific CD8(+) cytotoxic T ..
- Aurora-A kinase: a novel target of cellular immunotherapy for leukemiaToshiki Ochi
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, Japan
Blood 113:66-74. 2009..Our results indicate that cellular immunotherapy targeting Aur-A is a promising strategy for treatment of leukemia...
- Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen presentation during clearance of a persistent viral infectionHenning Lauterbach
Molecular and Integrative Neurosciences Department, The Scripps Research Institute, La Jolla, CA 92037, USA
J Exp Med 203:1963-75. 2006..Administration of exogenously derived pathogen-specific memory T cells (referred to as adoptive immunotherapy) to mice burdened with a persistent lymphocytic choriomeningitis virus (LCMV) infection from birth results ..
- Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cellMarcus O Butler
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Cancer Res 13:1857-67. 2007..To overcome this, we sought to establish a clinical grade culture system that can reproducibly generate antigen-specific cytotoxic T lymphocytes (CTL)...
- Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapyLisa Marie Serrano
University of Texas M D Anderson Cancer Center, Pediatrics Research Unit 853, 1515 Holcombe Blvd, Houston, TX 77030, USA
Blood 107:2643-52. 2006..approach to eliminating residual disease after allogeneic hematopoietic stem cell transplantation, adoptive immunotherapy after UCBT is constrained by the difficulty of generating antigen-specific T cells from functionally naive ..
- Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforinJennifer N Macgregor
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Cancer Res 66:4913-21. 2006..Ex vivo culture with IL-12 may improve CD8(+) T-cell immunotherapy of cancer in the absence of donor cell-derived IFN-gamma via perforin-mediated cytolysis...
- Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapyL Tramsen
Pediatric Hematology and Oncology, Children s Hospital III, Johann Wolfgang Goethe University, Frankfurt, Germany
Bone Marrow Transplant 43:13-9. 2009..This method of generating is suitable for future prospective trials designed to evaluate the effect of adoptive immunotherapy in hematopoietic transplant recipients with invasive aspergillosis.
- Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantationJ C Alvarnas
Department of Medicine, Stanford University Medical Center, California, USA
Biol Blood Marrow Transplant 7:216-22. 2001..CIK cells may be expanded from granulocyte colony-stimulating factor-mobilized PBPCs of patients undergoing autologous HCT. CIK cells may provide a potent tool for use in posttransplantation adoptive immunotherapy.
- Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blastsY C Linn
Department of Haematology, Singapore General Hospital, Singapore
Br J Haematol 116:78-86. 2002....
- Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectorsSara Bobisse
Department of Oncology, University of Padova, Padova, Italy
Cancer Res 69:9385-94. 2009..Overall, our results indicate that lentiviral vectors represent a valid tool for stable and high-intensity expression of transgenic TCR and support clinical exploitation of this approach for therapeutic application...
- Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitopeMalcolm S Mitchell
Center for Biological Therapy and Melanoma Research, University of California San Diego School of Medicine, San Diego, CA, USA
J Clin Oncol 20:1075-86. 2002..To study distribution and toxicity of cytolytic T lymphocytes (CTLs) against a single melanoma epitope...
- aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa-overexpressed breast cancerYi ting Jin
Department of Surgery, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai 200040, China
Oncol Res 17:59-68. 2008..The anticancer effects of 5-FU chemotherapy or adoptive immunotherapy and the synergic action of aPKC inhibitor against hASIPa-overexpressed HBC cells were tested...
- Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusionsD P Hart
Department of Haematology, University College London Hospital, London, UK
Br J Haematol 128:824-9. 2005..This retrospective pilot study forms the basis for a prospective study to clarify the utility of (18)F-FDG PET/CT in these patients...
- Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacityChy Anh Tran
Division of Hematology Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA
J Immunother 30:644-54. 2007..of patient-specific cell products to produce large numbers of T-lymphocytes in support of phase 2 adoptive immunotherapy trials for hematologic malignancies...
- Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cellsLukas Hunziker
Institute of Experimental Immunology, Department of Pathology, University of Zurich, Zurich, Switzerland
Eur J Immunol 32:374-82. 2002..of antiviral CTL after transfusion into persistently infected individuals is a serious limitation of adoptive immunotherapy protocols...
- Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applicationsAnn M Leen
Center for Cell and Gene Therapy, Department of Pediatrics, 6621 Fannin S, MC 3 3320, Houston, TX 77030, USA
Blood 103:1011-9. 2004..To date there is no therapy. The present study was motivated by the potential for using adoptive immunotherapy as either prophylaxis or treatment for Ad infections and associated diseases...
- Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytesHiroshi Kondo
Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755 8505, Japan
Anticancer Res 28:379-87. 2008..The clinical efficacy of immunotherapy using both dendritic cells pulsed with MUC1 peptide (MUC1-DC) and, cytotoxic T lymphocyte (CTL) sensitized with a pancreatic cancer, YPK-1, expressing MUC1 (MUC1-CTL) was evaluated...
- Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusionLarry W Kwak
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
Semin Oncol 31:37-46. 2004..Donor immunization with myeloma idiotype protein in the setting of a nonmyeloablative SCT may represent a novel strategy for the treatment of myeloma...
- Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemiaAlessandra Takatu
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 9:674-82. 2003..We conclude that DLI after nonmyeloablative HCT can increase the levels of donor cells contributing to hematopoiesis in recipients, inducing remissions of the hemolytic process and preventing complications associated with iron overload...
- Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasmsDavide Bagnara
Human Anatomy Section, Department of Experimental Medicine, University of Genoa, Genoa, Italy
Haematologica 94:967-74. 2009..Alpha-galactosylceramide (alpha-GalCer) is a glycolipid that can be presented to cytotoxic CD1d-restricted T cells. These reagents represent a potentially powerful tool for cell mediated immunotherapy...
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trialS Arai
Rush University Medical Center, Chicago, Illinois, USA
Cytotherapy 10:625-32. 2008....
- Schizophrenia and other mental disorders require long-term adoptive immunotherapyRudolf Wank
Institute of Immunology, Klinikum Innenstadt, University of Munich, Goethestrasse 31, 80336 Munich, Germany
Med Hypotheses 59:154-8. 2002..R. Lewis, S.J. Wiegand, R.M. Lindsay, Pharmacol. Biochem. Be 56 (1997) 131-137]. The hypothesis that adoptive immunotherapy is effective in psychiatric disorders will be supported by three case reports, in a patient with bipolar ..
- Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantationG E Georges
Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA 98109 1024, USA
Blood 95:3262-9. 2000..In the current study, we examined whether donor lymphocyte infusion (DLI) could be used as adoptive immunotherapy to convert mixed to complete donor chimerism...
- Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccineJ Banchereau
Baylor Institute for Immunology Research, Dallas, Texas 75204, USA
Cancer Res 61:6451-8. 2001..Regression of >1 tumor metastases were observed in seven of these patients. The overall immunity to MelAgs after DC vaccination is associated with clinical outcome (P = 0.015)...
- Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cellsLi Xin Wang
Center for Surgery Research, Division of Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Cancer Res 65:9547-54. 2005T-cell adoptive immunotherapy for stringent murine tumor models, such as intracranial, s.c., or advanced pulmonary metastases, routinely uses lymphodepletive conditioning regimens before T-cell transfer, like recent clinical protocols...
- Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseasesS Sakaguchi
Precursory Research for Embryonic Science and Technology PRESTO, Research and Development Corporation of Japan JRDC, Tsukuba Life Science Center
J Immunol 155:1151-64. 1995..Abnormality of this T cell-mediated mechanism of peripheral tolerance can be a possible cause of various autoimmune diseases...
- Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipientsB Savoldo
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Transplantation 72:1078-86. 2001..b>Adoptive immunotherapy may have therapeutic potential in this setting, but there is little experience in generating autologous ..
- Adoptive immunotherapy of HCMV infectionM Kapp
Medizinische Klinik und Poliklinik II, Julius Maximilians University of Wurzburg, Germany
Cytotherapy 9:699-711. 2007..In this review, we aim to provide a comprehensive synopsis of the current standard of knowledge concerning cellular HCMV-specific immunotherapeutic approaches...
- CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapyK A Ward
Bone Marrow Transplant Programme, Alfred Hospital, Melbourne, Australia
Cytotherapy 8:130-40. 2006..However, significant heterogeneity within DC preparations is apparent and supports the existence of several distinct DC subpopulations. This study aimed to expand and characterize CD34+ DC for use in immunotherapy...
- Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancerAnnemieke de Jong
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Building 1 E3 Q, 2300 RC Leiden, The Netherlands
Int J Cancer 114:274-82. 2005..These HPV16E6-specific CD4(+) T cells may turn out to be an essential component of future adoptive T cell therapy for advanced cervical cancer, by orchestrating CTL dependent and independent tumoricidal mechanisms...
- Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot studyHirohito Kobayashi
Department of Urology, Tokyo Women s Medical University, 8 1 Kawada cho, Shinjuku ku, Tokyo 162 8666, Japan
Cancer Immunol Immunother 56:469-76. 2007..have been used to improve the prognosis of patients with advanced renal cell carcinoma (RCC), adoptive immunotherapy using gamma-delta (gammadelta) T cells has not yet been tried...
- Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1Toru Kawaoka
Department of Digestive Surgery and Surgical Oncology Department of Surgery II, Yamaguchi University Graduate School of Medicine, Yamaguchi 755 8505, Japan
Oncol Rep 20:155-63. 2008..In this study, we performed adoptive immunotherapy (AIT) in patients with PC with CTLs stimulated by the MUC1-expressing human PC cell line YPK-1...
- Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imagingMatthias Edinger
Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, CA, USA
Blood 101:640-8. 2003..The complex cellular processes in bone marrow transplantation and antitumor immunotherapy, previously inaccessible to investigation, can now be revealed in real time in living animals...
- Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantationKatia Perruccio
Department of Clinical and Experimental Medicine, IRCCS Foundation on Transplantation Biotechnologies, University of Perugia, Via Brunamonti 51, 06123, Italy
Blood Cells Mol Dis 40:76-83. 2008..Consequently, a clinical trial is planned to incorporate infusion of photo-allodepleted donor T cells after haploidentical stem cell transplantation with the aim of decreasing infection-related mortality...
- In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoireWilliam Y Ho
Program in Immunology, Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, WA 98109, USA
J Immunol Methods 310:40-52. 2006..on in vivo vaccination trials, but also to generate T-cell lines or clones that could be used directly for adoptive immunotherapy approaches...
- Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approachPouneh Dokouhaki
Toronto General Research Institute, University Health Network, Toronto, Canada
Cancer Lett 297:126-36. 2010gammadelta T cells can be an option for adoptive immunotherapy of cancer. The major obstacle to clinical application of gammadelta T cells is their low number and lack of a reliable method to expand them consistently and efficiently...
- Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patientsViviana P Lutzky
EBV Biology Laboratory, Division of Immunology, Australian Centre for Vaccine Development, The Queensland Institute of Medical Research, The Royal Brisbane Hospital, 300 Herston Road, Herston, Brisbane, QLD 4006, Australia
Immunol Cell Biol 87:481-8. 2009..In order to maximize the expansion of LMP-specific CTL in vitro for use in adoptive immunotherapy of nasopharyngeal carcinoma patients, we used lymphoblastoid cell lines coated with synthetic peptides ..
- Next generation adoptive immunotherapy--human T cells as carriers of therapeutic nanoparticlesM W Mortensen
Nano Science Center, University of Copenhagen, Universitetsparken 5, DK 2100 Copenhagen, Denmark
J Nanosci Nanotechnol 7:4575-80. 2007An important step in adoptive immunotherapy in general and specifically with respect to cancer treatment is the initiation of an inflammatory T cell response at the tumor site...
- Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemiaJ K Orleans-Lindsay
Department of Haematology, Royal Free University College Medical School, London, UK
Clin Exp Immunol 126:403-11. 2001Evidence of an immune mediated graft-versus-leukaemia effect has led to the belief that T and NK cell based adoptive immunotherapy can constitute effective treatment for relapsed leukaemias...
- Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancerMona Karlsson
Karolinska Institute, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Ann Surg Oncol 17:1747-57. 2010..We have conducted a pilot study of a novel adoptive immunotherapy, using autologous, in vitro expanded lymphocytes isolated from the tumor-draining sentinel lymph node.
- Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signalingRajani Ravi
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
Cancer Res 66:1730-9. 2006....
- Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytesKarin C M Straathof
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, 1102 Bates St, Suite 1120, Houston, TX 77030, USA
Blood 105:1898-904. 2005..These results demonstrate that administration of EBV-specific CTLs to patients with advanced NPC is feasible, appears to be safe, and can be associated with significant antitumor activity...
- Natural-killer-cell-based treatment in haematopoietic stem-cell transplantationJakob R Passweg
Service d Hematologie, Departement Medecine Interne, Hopitaux Universitaires de Geneve, Geneve, Switzerland
Best Pract Res Clin Haematol 19:811-24. 2006b>Adoptive immunotherapy using natural killer (NK) cells is currently under investigation, especially in situations where anti-neoplastic effect is needed but infusion of T cells is considered hazardous, such as in recipients of ..
- CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapyJ L Schultze
Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
J Clin Invest 100:2757-65. 1997..We, therefore, contend that CD40-activated B cells are an alternative source of highly efficient APCs with which to generate antigen-specific T cells ex vivo for autologous adoptive immunotherapy.
- A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaMark E Dudley
Surgery Branch, National Cancer Institute, Building 10, Room 2B08, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Immunother 25:243-51. 2002..a phase I clinical trial using nonmyeloablative, lympho-depleting chemotherapy in combination with adoptive immunotherapy in patients with metastatic melanoma...
- Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferonJacques Banchereau
Baylor Institute for Immunology Research, Dallas, TX, USA
J Immunother 28:505-16. 2005..Overall, these results suggest that IFN-alpha-activated CD34-DCs are safe but elicit only limited immune responses, underscoring the need to test different DC maturation factors...
- Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanomaM E Dudley
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
J Immunother 24:363-73. 2001..The lack of clinical effectiveness of this protocol suggests that transfer of different or additional cell types or that modulation of the recipient host environment is required for successful therapy...
- CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancerMark J Smyth
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia
J Immunol 176:1582-7. 2006..Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity...
- A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphomaThomas Leemhuis
Division of Bone Marrow Transplantation, Stanford University Medical Center, California, USA
Biol Blood Marrow Transplant 11:181-7. 2005....
- Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapyE Goulmy
Department of Immunohematology and Blood Bank, Leiden University Hospital, The Netherlands
Immunol Rev 157:125-40. 1997..Directly relevant is the utility of mHag molecular typing for diagnostics in BM donor selection. Most promising is the use of mHag-specific cytotoxic T cells for adoptive immunotherapy of leukemia.
- Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunityLei Shen
Center for Cell and Gene Therapy, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
Nat Biotechnol 22:1546-53. 2004..This study has implications for understanding the regulation of antigen presentation and for developing more effective tumor vaccines by silencing the critical brake in antigen presentation...
- Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myelomaNicolaus Kroger
Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
Blood 104:3361-3. 2004..The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus ..
- Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunityChristian S Hinrichs
National Cancer Institute, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 106:17469-74. 2009..better than those derived from effector memory populations, suggesting that they are superior for use in adoptive immunotherapy studies...
- Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in childrenU Koehl
University Hospital Frankfurt, Pediatric Hematology and Oncology, Frankfurt, Germany
Klin Padiatr 217:345-50. 2005..For a possible benefit of post transplant treatment with NK cells after haploidentical stem cell transplantation (haplo-SCT) we developed a clinical scale procedure for NK cell processing observing Good Manufacturing Practice (GMP)...
- Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapyQiao Li
Division of Surgical Oncology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0932, USA
Cancer Res 63:2546-52. 2003..of TDLN cells activated through 4-1BB in conjunction with CD3/CD28 pathways was examined using an adoptive immunotherapy model...
- The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsetsDavid A Horwitz
Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles 90033 1034, USA
J Leukoc Biol 74:471-8. 2003..Finally, the potential use of regulatory T cells generated ex vivo as an adoptive immunotherapy for certain autoimmune diseases, to prevent organ graft rejection, or to prevent pathologic host responses ..
- CD8+ T Cell Immunity to CytomegalovirusStanley R Riddell; Fiscal Year: 2010..by this project have investigated the immunobiology of CMV infection and developed strategies for specific adoptive immunotherapy with CD8+ T cell clones to correct deficiencies of T cell immunity that permit the progression of CMV ..
- Imaging Infused CD19 Specific T Cells in the TumorLAURENCE COOPER; Fiscal Year: 2007..Gene therapy can improve the therapeutic potential of adoptive immunotherapy and as recently published (Science 2006 Aug 31), infusion of genetically modified T cells with redirected ..
- CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCYJohn Levine; Fiscal Year: 2006..The candidate proposes a strategy of a low intensity conditioned transplant followed by prophylactic adoptive immunotherapy as a means of preventing relapse through GVL while minimizing risk of GVHD or regimen-related toxicity. Dr...
- Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent GliomasLinda M Liau; Fiscal Year: 2010..Toward these goals, we have actively explored permutations of local adoptive immunotherapy for human malignant gliomas with autologous and allogeneic effector cells...
- Leukocyte-Endothelial Adhesion in Tumor ImmunitySharon S Evans; Fiscal Year: 2010..molecules (adhesion receptors, chemokines) that recruit T cells in a murine B16 melanoma model of adoptive immunotherapy. Complementary in situ imaging studies will investigate the contribution of endogenous human IL-6 in ..
- SPORE in LymphomaRichard Ambinder; Fiscal Year: 2007..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
- T CELL TRAFFICKING IN ADOPTIVE CELLULAR IMMUNOTHERAPYLloyd Stoolman; Fiscal Year: 2000..Finally, the collaboration between the PI and co-PI will enhance productivity and ensure the rapid transfer of information from a pre-clinical to a clinical setting. ..
- Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus MacaquesLeslie S Kean; Fiscal Year: 2010..1) most novel therapies for BMT (including T cell costimulation blockade, T cell adhesion blockade and adoptive immunotherapy with regulatory T cells) cannot be accurately tested in either murine or canine models for aGvHD and (2) ..
- CTLA-4 Blockade in Allo Stem Cell TransplantationEdward Ball; Fiscal Year: 2005..There exists considerable evidence that adoptive immunotherapy in the form of a donor T-cell mediated graft-versus-malignancy (GVM) is an important component of the ..
- CLONAL GVL/GVH REACTIONS AND ADOPTIVE IMMUNOTHERAPYROBERT TRUITT; Fiscal Year: 1990..The proposed studies are a systematic approach to optimizing the GVL effect while minimizing the GVH effect of cloned CTL. In addition, they will enable us to gain significant new insights into the pathogenesis of clonal GVH reactions...
- Novel Cellular Therapies for Ph+ leukemiaRICHARD A contact VAN ETTEN; Fiscal Year: 2010..well- characterized mouse model of CML and Ph+ B-ALL to determine the efficacy and cellular mechanisms of adoptive immunotherapy with allogeneic T-lymphocytes or natural killer (NK) cells...
- Strategies to Enhance Adoptive Transfer T Cell ClonesStanley Riddell; Fiscal Year: 2009..augment an immune response in vivo and provide therapeutic benefit, and there is increasing evidence that adoptive immunotherapy with T cells has therapeutic activity in human malignancies and infection...
- Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.MARY DISIS; Fiscal Year: 2009..We therefore believe that this 2 year proposal is consonant with Recovery Act goals by promoting job creation, economic development, and accelerating the pace and achievement of scientific research. ..
- Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.MARY L contact DISIS; Fiscal Year: 2010..We therefore believe that this 2 year proposal is consonant with Recovery Act goals by promoting job creation, economic development, and accelerating the pace and achievement of scientific research. ..
- LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMTDon Diamond; Fiscal Year: 2002..An adoptive immunotherapy strategy using CTL has proved successful but is impractical for general use in BMT centers...
- EVALUATION OF ADOPTIVE T CELL THERAPY FOR HIVDEBORAH LEWINSOHN; Fiscal Year: 2002..In conjunction with others in the laboratory, I have evaluated adoptive immunotherapy of HIV infection with in vitro expanded, autologous, gene-modified HIV- specific CD8+ CTL clones to ..
- Lentiviral Vectors for TCR Immunotherapy Targeted to melanomaBoro Dropulic; Fiscal Year: 2006..Lentigen's collaborator Dr. Michael Nishimura has helped pioneer adoptive immunotherapy as a potential therapeutic approach for melanoma...